Srihari Sritharan, PhD

Venture Fellow

Dr. Srihari (Sri) Sritharan is a Venture Fellow at Kaleida Capital, where he evaluates investments across neurotechnology and neuro-biopharma. As a Brown and UPenn-trained neuroengineer currently serving as Director of Business Development at Beacon Biosignals, he brings experience spanning neurotechnology research and strategic transactions, with a focus on advancing breakthrough technologies from scientific discovery to commercialization. Recently, Dr. Sritharan supported high-impact industry partnerships, including a $100M+ collaboration with Takeda at Beacon Biosignals and a nearly $1B RNA therapeutics licensing transaction for Acadia Pharmaceuticals' neurodegenerative disease pipeline. Earlier in his career, his doctoral research at the University of Pennsylvania focused on wireless neuromodulation for sensory restoration, contributing to advances in next-generation neurotechnology and brain–computer interfaces. Dr. Sritharan holds a PhD in Neuroscience from the University of Pennsylvania and a BS in Neuroscience from Brown University.